Genital Herpes

Genital Herpes Treatment Market to See Incredible Growth During 2017-2025

Sexually transmitted diseases (STD) are also known as venereal diseases, are generally caused by infections that are transmitted from one person to the other during sexual intercourse. Sexually transmitted infections (STI) are caused by more than 30 different viruses, bacteria, and parasites. Common type of STDs include chlamydia, gonorrhea, syphilis, genital herpes, and trichomoniasis. Genital herpes is a STI caused by herpes simplex virus. Blisters on or around genitals, vaginal discharge, pelvic pain, and penile discharge are some common symptoms of genital herpes. As stated by the World Health Organization (WHO) in December 2015, around 1 million sexually transmitted infections are developed every day, globally. As per WHO, in the U.S. around 15% of people with herpes simplex virus infection report prior diagnosis of genital herpes. Accurate diagnostic tests such as competitive polymerase chain reactions (PCR), DNA enzyme immunoassay hybridization, real-time PCR assay are extensively used to diagnose STIs in developed countries. These tests are useful for the diagnosis of asymptomatic infections. These diagnostic tests are very expensive, the only inexpensive, rapid tests currently available for STIs are for syphilis and HIV.

We offer generic Viagra, Sildenafil Citrate 100mg, under brand name Suhagra, this medicines is used for treatment ED for men’s.

treatment of these infections is expected to drive the genital herpes treatment market during forecasting period. In order to address the urgent need of better treatment for sexually transmitted infections and to combat rapid development of antiviral-resistant species, governments across the world have taken initiatives which would support the growth of genital herpes treatment market. The Innovative Medicine Initiative (IMI) in partnership with the European Union and the pharmaceutical industry in Europe aims at developing innovative therapeutic alternatives to create new opportunities for STD treatment. This, in turn, is projected to support the expansion of the genital herpes treatment market.

The global genital herpes treatment market has been segmented based on type of drugs, distribution channel, and geography. In general antiviral therapy is prescribed in line to treat genital herpes. Based on type of drugs, the genital herpes treatment market has been divided into acyclovir, famciclovir, valacyclovir, and others. Acyclovir is commonly used as first line antiviral agent and is expected to hold a significant share of the market during the forecast period. There are few antivirals such as valacyclovir used in herpes infection also used to treat genital herpes. Based on distribution channels, the genital herpes treatment market has been divided into hospitals, retail pharmacy, and online pharmacy. Retail pharmacy accounted for a considerable share of the market due to presence of generic market. The online pharmacy segment is expected to expand in the near future due to the rise in adoption of online purchases in developed countries such as the U.S.

In terms of geography, the global genital herpes treatment market has been categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the global genital herpes treatment market. The region is expected to be a highly attractive market for STD drugs during the forecast period. Dominance of the region can be attributed to the rising prevalence of the disease and high cost of drugs. North America and Europe are expected to remain the prominent markets due to high consumption of antiviral drugs. The market in Asia Pacific and Latin America is expected to expand in later stage of forecast period due to rising awareness regarding treatments for genital herpes.

Herpes-2 Vaccine

Herpes-2 Vaccine Candidate Update

HSV-2 vaccine candidate VCL-HB01 is in late stage clinical trial

May 1st, 2018 – Various herpes vaccine candidates have been in development since the 1920s.

But, in the intervening nine decades, all research efforts for herpes simplex viruses 1 and 2, have failed to produce an effective vaccine.

These disappointing research efforts are primarily due to the variability of Herpesviruses, of which there are over 100 types.

Moreover, Herpesviruses are known for their ability to establish lifelong infections.

Other herpesviruses include varicella-zoster virus (HHV-3), Epstein–Barr virus ( HHV-4), human cytomegalovirus (HHV-5), human herpesvirus 6A and 6B (HHV-6A and HHV-6B), human herpesvirus 7 (HHV-7), and Kaposi’s sarcoma-associated herpesvirus  (HHV-8).

With the success of the Varicella vaccine, known as the chickenpox vaccine, and the zoster vaccine for shingles and postherpetic neuralgia, many people are asking when will a herpes simplex virus become available.

This unmet consumer demand is because HSV-2 causes genital herpes and is a lifelong infection.

According to the Centers for Disease Control and Prevention (CDC), genital herpes is widespread throughout the world and is generally sexually transmitted.

Over 24 million people in the United States are infected with HSV-2 and there are 776,000 new infections each year.

There is one HSV-2 vaccine candidate in late-stage clinical trials. VCL-HB01 is Vical’s Therapeutic HSV-2 Vaccine

  VCL-HB01 is a bivalent DNA vaccine candidate, encoding full-length HSV-2 UL-46 and gD antigens was developed in collaboration with the University of Washington.

In a Phase 1/2 randomized, double-blind, placebo-controlled trial of 165 HSV-2 infected adults, VCL-HB01 demonstrated a statistically significant reduction in genital lesion rate compared to baseline.

This good news was followed by a Phase 2 randomized, double-blind, placebo-controlled trial in approximately 225 HSV-2 infected adults. They receive VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses.

This study has been underway since September 2016 to evaluate the primary efficacy endpoint of reduction in annualized recurrence rates over a 12-month follow-up period.

Recurrence rate is one of the most clinically meaningful endpoints as it provides information on both the number and spacing of recurrences over time in the chronic disease setting.

Until this vaccine candidate, or another one comes to market, HVS-2 infected people can only manage the ongoing symptoms with medications.

Antivirals, such as acyclovir, famciclovir, and valacyclovir are the most effective medications available for people infected with HSV.

These medications can help to reduce the severity and frequency of symptoms.

But, these antivirals cannot cure the HSV-2 infection. (Source)

Our company also offers another interested medicines, you may interested  in Modafinil for brain activity, Valdoxan for relax, or Cenforce for treatment erectile dysfuntion for mens.

Market Analysis

Future Demand, Market Analysis & Outlook to 2022 on Valacyclovir

The Valacyclovir HCl Market report covers the current market size of Valacyclovir HCl and its growth rates based on 5year historic data. The Valacyclovir HCl Market Report Provides growth history, sales channel, manufacturers profiled in Valacyclovir HCl industry, a market share of product type, application and scope of a region in detail. The Market report also consists key drivers and limiting factors affect the Valacyclovir HCl market growth, change in industry trends or challenges faced by Valacyclovir HCl manufacturers in forecast years. Source

Also our company offer to try another medicines to make an order, we have popular medication as like: Lyrica | Xifaxan | Nexavar, and others, we have wide choice, and guarantee shipping from India to USA, UK, AU, Europe.

Valaciclovir (INN) or valacyclovir (USAN) is an antiviral drug used in the management of herpes simplex, herpes zoster (shingles), and herpes B. It is a prodrug, being converted in vivo to aciclovir. It is marketed by GlaxoSmithKline under the trade names Valtrex and Zelitrex. Valaciclovir has been available as a generic drug in the U.S. since November 25, 2009.